Hypophosphatasia is caused by the deficiency of activity of the non-specific alkaline phosphatase (TNSALP), resulting in a defect of bone mineralization. Asfotase alfa is an FDA-approved drug used to treat hypophosphatasia, a rare inherited, metabolic disease that affects the development of bones and teeth. The current article highlights the potential role of this molecule in managing hypophosphatasia.(HPP) Asfotase Alpha It's a tissue non-specific alkaline phosphatase.
Asfotase alfa treats a rare metabolic disease called hypophosphatasia. It offers a treatment option as it is the first and only treatment available for patients suffering from perinatal/infantile- and juvenile-onset hypophosphatasia. Mechanism HPP is caused by a deficiency in Tissue-Nonspecific Alkaline Phosphatase (TNSALP) enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic…
